Skip to content
Vol. 1Global Edition
Icon MagazineProfiles of the people who build
Data: TradingView

Hiroaki Suga: Pioneering Peptides for Tomorrow's Treatments

Hiroaki SugaFounder, PeptiDream16 November 20262 min read

Hiroaki Suga stands at the intersection of advanced scientific discovery and entrepreneurial endeavor. As a biochemist and businessman, his career has been marked by significant contributions to understanding biological processes and then leveraging that knowledge to establish a company focused on developing novel therapeutics. His work has laid the foundation for new approaches in medicine, particularly through the creation of PeptiDream.

Scientific Foundations

Suga’s academic journey began with engineering studies at Okayama University, followed by research at the University of Lausanne and a Ph.D. in chemistry from the Massachusetts Institute of Technology. His postdoctoral research at Harvard Medical School preceded his independent academic career, which included a faculty position at the University at Buffalo before he joined the University of Tokyo in 2003. Throughout his scientific career, Suga has been recognized for his pioneering work on artificial ribozymes, specifically flexizymes, and their application in mRNA display, a method known as RaPID (random nonstandard peptide integrated discovery). These discoveries illuminate the functions and dysfunctions of RNA and proteins, offering new strategies to harness these biopolymers to address human diseases. His profound impact on the field was acknowledged with the Wolf Prize in Chemistry, an honor shared for advancing understanding and therapeutic applications of these biological molecules. He has authored over 250 scientific articles and contributes to the scientific community as chair of the editorial board at RSC Chemical Biology and an associate editor at Angewandte Chemie.

Establishing PeptiDream

Building on his extensive scientific background, Suga founded PeptiDream Inc. in Tokyo. This biopharmaceutical start-up was established with the goal of discovering and developing non-standard peptide therapeutics. The company’s core mission involves addressing unmet medical needs through innovative approaches. PeptiDream’s research and development efforts extend to investigating peptide drug conjugates (PDC), as well as other peptide and small molecule-based drugs. The company’s strategy is rooted in translating complex biochemical insights into practical applications that can lead to new treatment options for patients.

Global Impact and Growth

PeptiDream has grown significantly since its inception, evolving into a publicly traded entity listed on the Tokyo First Stock Exchange Market. The company’s market capitalization reflects its substantial presence in the biopharmaceutical sector. A key aspect of PeptiDream’s operational model is its extensive network of partnerships with pharmaceutical companies across the globe. These collaborations are instrumental in advancing the discovery and development of its therapeutic candidates, ensuring that its innovative approaches can reach a wider patient population and contribute to global healthcare solutions.

Career timeline

  1. 1963Born in Kita-ku
  2. 1990Studies at Massachusetts Institute of Technology
  3. 1994Joins Massachusetts General Hospital
  4. 1997Leaves Massachusetts General Hospital
  5. 1997Joins University at Buffalo
  6. 2003Leaves University at Buffalo
  7. 2003Joins University of Tokyo
  8. 2006Founds PeptiDream
  9. 2019Awarded Vincent du Vigneaud Award
  10. 2022Awarded Prelog Medal and Lecture
  11. 2023Awarded Wolf Prize in Chemistry
  12. 2026Awarded Fellow of the Royal Society

From Wikidata, retrieved 2026-11-16. Spotted an error? Wikidata can be corrected by anyone.

Sources

  1. Wikipedia: Hiroaki Suga
  2. Wikidata

Written by Icon Magazine from these sources, and fact-checked against them.

Keep reading

More profiles